ProCE Banner Activity

Expert Takes on Key Questions in GVHD

Clinical Thought
In this commentary, Corey Cutler, MD, MPH, FRCPC; David Miklos, MD, PhD; and Robert Zeiser, MD, address key questions about the treatment of patients with graft versus host disease (GVHD).

Released: May 04, 2022

Expiration: May 03, 2023

No longer available for credit.

Share

Faculty

Corey Cutler

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Incyte Corporation

Faculty Disclosure

Primary Author

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey Cutler, MD, MPH, FRCPC, has disclosed that he has received consulting fees from CareDx, Fresenius Kabi, Incyte, Janssen, Jazz, Kadmon, and Mesoblast and other financial or material support from Omeros.